R&D-Biopharmaceuticals is a biotechnology company focusing on the pre-clinical and clinical development of unique small molecules deriving from natural products for diseases with unmet medical need.
The Company has exclusive access to the natural product class of the tubulysins discovered by Prof. Höfle and to next generation epothilones, a highly promising new drug class for the treatment of cancer.
Tubulysins / Cytolysins
The recently discovered natural product class of the tubulysins show a very high cytotoxic activity against in vitro and in vivo tumour models, especially against resistant tumour cell lines. >> more
The FDA approved the first epothilone drug (IXEMPRA™) for BMS in October 2007. Further drug candidates of this natural products class are currently investigated in several clinical trials by several companies. >> more
R&D GmbH, Am Klopferspitz 19, D-82152 Planegg-Martinsried © 2010